WuXi Biologics (Cayman) Inc. (HKG:2269)
25.70
+0.65 (2.59%)
Jul 8, 2025, 4:08 PM HKT
WuXi Biologics Revenue
In the year 2024, WuXi Biologics had annual revenue of 18.68B CNY with 9.63% growth. WuXi Biologics had revenue of 10.10B in the half year ending December 31, 2024, with 25.29% growth.
Revenue
18.68B CNY
Revenue Growth
+9.63%
P/S Ratio
5.26
Revenue / Employee
1.49M CNY
Employees
12,575
Market Cap
104.58B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.49B |
Hansoh Pharmaceutical Group Company | 13.05B |
Innovent Biologics | 10.03B |
JD Health International | 61.89B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
CSPC Pharmaceutical Group | 28.99B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
WuXi Biologics News
- 8 days ago - WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL - PRNewsWire
- 20 days ago - Focus: China pharma projects disrupted by Sino-US tensions - Reuters
- 22 days ago - Hong Kong stocks waver on China’s mixed economic data - South China Morning Post
- 4 weeks ago - WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu - PRNewsWire
- 5 weeks ago - Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade - South China Morning Post
- 7 weeks ago - WuXi Biologics: Eyes On Long-Term Risks And Near-Term Outlook (Rating Downgrade) - Seeking Alpha
- 7 weeks ago - WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA - PRNewsWire
- 2 months ago - Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report - PRNewsWire